WO2005050203A3 - Materiaux biologiques et utilisations correspondantes - Google Patents

Materiaux biologiques et utilisations correspondantes Download PDF

Info

Publication number
WO2005050203A3
WO2005050203A3 PCT/GB2004/004795 GB2004004795W WO2005050203A3 WO 2005050203 A3 WO2005050203 A3 WO 2005050203A3 GB 2004004795 W GB2004004795 W GB 2004004795W WO 2005050203 A3 WO2005050203 A3 WO 2005050203A3
Authority
WO
WIPO (PCT)
Prior art keywords
ctgf
ctgf receptor
compounds
fibrosis
test sample
Prior art date
Application number
PCT/GB2004/004795
Other languages
English (en)
Other versions
WO2005050203A2 (fr
Inventor
Roger Maxwell Mason
Nadia Abdel Wahab
Original Assignee
Imp College Innovations Ltd
Roger Maxwell Mason
Nadia Abdel Wahab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imp College Innovations Ltd, Roger Maxwell Mason, Nadia Abdel Wahab filed Critical Imp College Innovations Ltd
Priority to EP04798515A priority Critical patent/EP1718979A2/fr
Priority to JP2006540577A priority patent/JP2007515162A/ja
Priority to AU2004292013A priority patent/AU2004292013A1/en
Priority to CA002546401A priority patent/CA2546401A1/fr
Publication of WO2005050203A2 publication Critical patent/WO2005050203A2/fr
Publication of WO2005050203A3 publication Critical patent/WO2005050203A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Dermatology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

La présente invention concerne un procédé permettant d'identifier et/ou d'élaborer des composés afin de les utiliser pour réduire et/ou prévenir la fibrose, lequel procédé comprend les étapes qui consistent à fournir un récepteur CTGF; à fournir un échantillon d'essai; à fournir un agoniste du récepteur CTGF; à exposer le récepteur CTGF à l'échantillon d'essai; ultérieurement ou simultanément à exposer le récepteur CTGF à l'agoniste du récepteur CTGF; à détecter et/ou à mesurer la quantité d'activation du récepteur CTGF; à comparer la quantité d'activation du récepteur CTGF détectée et/ou mesurée en présence de l'échantillon d'essai avec la quantité d'activation du récepteur CTGF détectée et/ou mesurée en l'absence d'un échantillon d'essai; à déterminer si un composé réduit et/ou prévient la fibrose compte tenu du fait qu'il ne provoque aucune augmentation ou réduction de l'activation du récepteur CTGF. Cette invention concerne également des composés permettant de réduire et/ou de prévenir la fibrose, ainsi que les utilisations de ces composés.
PCT/GB2004/004795 2003-11-18 2004-11-15 Materiaux biologiques et utilisations correspondantes WO2005050203A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP04798515A EP1718979A2 (fr) 2003-11-18 2004-11-15 Methodes de criblage utilisant le ctgf et le recepteur trka pour l'identification de composes pour le traitement de la fibrose
JP2006540577A JP2007515162A (ja) 2003-11-18 2004-11-15 線維症の治療において使用する化合物の同定のためのｃｔｇｆ及びｔｒｋａレセプターを使用するスクリーニング方法
AU2004292013A AU2004292013A1 (en) 2003-11-18 2004-11-15 Methods for screening using CTGF and TRKA receptor for the identification of compounds for use in treatment of fibrosis
CA002546401A CA2546401A1 (fr) 2003-11-18 2004-11-15 Materiaux biologiques et utilisations correspondantes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0326780.4 2003-11-18
GBGB0326780.4A GB0326780D0 (en) 2003-11-18 2003-11-18 Biological materials and uses thereof

Publications (2)

Publication Number Publication Date
WO2005050203A2 WO2005050203A2 (fr) 2005-06-02
WO2005050203A3 true WO2005050203A3 (fr) 2005-11-17

Family

ID=29763971

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/004795 WO2005050203A2 (fr) 2003-11-18 2004-11-15 Materiaux biologiques et utilisations correspondantes

Country Status (7)

Country Link
EP (1) EP1718979A2 (fr)
JP (1) JP2007515162A (fr)
CN (1) CN1906491A (fr)
AU (1) AU2004292013A1 (fr)
CA (1) CA2546401A1 (fr)
GB (1) GB0326780D0 (fr)
WO (1) WO2005050203A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0326778D0 (en) * 2003-11-18 2003-12-24 Imp College Innovations Ltd Biological materials and uses thereof
WO2006102333A2 (fr) * 2005-03-21 2006-09-28 Alcon Manufacturing, Ltd. Utilisation d'agents inhibiteurs de liaison et de signalisation du facteur de croissance de tissus conjonctifs (ctgf) via le complexe recepteur trka/p75ntr pour la prevention de troubles oculaires lies au cgtf
US8946172B2 (en) 2008-08-25 2015-02-03 Excaliard Pharmaceuticals, Inc. Method for reducing scarring during wound healing using antisense compounds directed to CTGF
CN103429270B (zh) 2008-08-25 2016-11-23 埃克斯雷德制药有限公司 阻止结缔组织生长因子的反义核苷酸及其用途
EP2169059A1 (fr) * 2008-09-25 2010-03-31 Academisch Medisch Centrum bij de Universiteit van Amsterdam Supports et procédés de compensation, prévention et/ou détermination de fibrose ou risque de fibrose
EP2221387A1 (fr) 2009-02-19 2010-08-25 Université de la Méditerranée Gène de sensibilité à la fibrose et ses utilisations
SI2670411T1 (sl) 2011-02-02 2019-06-28 Excaliard Pharmaceuticals, Inc. Protismiselne spojine, ki so usmerjene na rastni faktor veznega tkiva (CTGF), za uporabo v postopku zdravljenja keloidov ali hipertrofnih brazgotin
CN104302780B (zh) 2011-08-05 2017-04-12 艾克斯-马赛大学 纤维变性易感性il22ra2基因及其用途
KR101467109B1 (ko) * 2013-07-10 2014-12-01 영남대학교 산학협력단 Ｂｉｘ02189 화합물을 유효성분으로 포함하는 폐섬유증 예방 또는 치료용 조성물
WO2015120136A1 (fr) 2014-02-05 2015-08-13 VM Oncology LLC Compositions de composés et leurs utilisations
WO2020238998A1 (fr) * 2019-05-30 2020-12-03 Sunshine Lake Pharma Co., Ltd. Anticorps anti-trka et leurs utilisations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555322B1 (en) * 1999-08-27 2003-04-29 Fibrogen, Inc. α2-macroglobulin receptor as a receptor for CTGF

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555322B1 (en) * 1999-08-27 2003-04-29 Fibrogen, Inc. α2-macroglobulin receptor as a receptor for CTGF

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 2000, WONG S T ET AL: "Treatment for autonomic dysreflexia using trkA-IgG after spinal cord injury", XP002336070, Database accession no. PREV200100135018 *
LEASK ANDREW ET AL: "Insights into the molecular mechanism of chronic fibrosis: The role of connective tissue growth factor in scleroderma.", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 122, no. 1, January 2004 (2004-01-01), pages 1 - 6, XP008049522, ISSN: 0022-202X *
POLLOCK GRAEME S ET AL: "TrkB receptor signaling regulates developmental death dynamics, but not final number, of retinal ganglion cells.", JOURNAL OF NEUROSCIENCE, vol. 23, no. 31, 5 November 2003 (2003-11-05), pages 10137 - 10145, XP002335976, ISSN: 0270-6474 *
RACHFAL AMY W ET AL: "Connective tissue growth factor (CTGF/CCN2) in hepatic fibrosis.", HEPATOLOGY RESEARCH, vol. 26, no. 1, May 2003 (2003-05-01), pages 1 - 9, XP002335977, ISSN: 1386-6346 *
SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 26, no. 1-2, 2000, 30TH ANNUAL MEETING OF THE SOCIETY OF NEUROSCIENCE; NEW ORLEANS, LA, USA; NOVEMBER 04-09, 2000, pages Abstract No. - 864.4, ISSN: 0190-5295 *
WAHAB NADIA ABDEL ET AL: "Connective tissue growth factor CCN2 interacts with and activates the tyrosine kinase receptor TrkA", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol. 16, no. 2, February 2005 (2005-02-01), pages 340 - 351, XP008049530, ISSN: 1046-6673 *

Also Published As

Publication number Publication date
AU2004292013A1 (en) 2005-06-02
CN1906491A (zh) 2007-01-31
JP2007515162A (ja) 2007-06-14
WO2005050203A2 (fr) 2005-06-02
GB0326780D0 (en) 2003-12-24
CA2546401A1 (fr) 2005-06-02
EP1718979A2 (fr) 2006-11-08

Similar Documents

Publication Publication Date Title
PL1776587T3 (pl) Zastosowanie C3A i jego pochodnych jako biomarkera do leczenia gruczolaka i/lub raka jelita grubego; metody diagnostyczne i testy z ich użyciem
WO2008041953A3 (fr) Diagnostic et traitement de la dingue
WO2003043487A3 (fr) Procede d'utilisation d'une proteine non anticorps permettant de detecter et de mesurer un analyte
WO2003106964A3 (fr) Procedes et dispositifs a haut rendement permettant de doser des analytes dans un echantillon fluidique
WO2002040998A3 (fr) Kit et procede permettant la detection d'analytes multiples avec des mesures permettant la referenciation de la densite d'elements de reconnaissance immobilises
WO2004099432A3 (fr) Identification de biomarqueurs permettant de detecter la presence d'un cancer du pancreas
WO2003066876A3 (fr) Appareil et procedes permettant de discriminer un agent a l'aide de matiere biologique
WO2003016527A3 (fr) Procede permettant de detecter un stress oxydatif et trousse destinee a la mise en oeuvre de ce procede
WO2006036212A3 (fr) Edulcorants sans sucre a utiliser dans des dispositifs d'essai
WO2002046746A3 (fr) Procede de detection de metabolites de la vitamine d
EP1652676A3 (fr) Systèmes et méthodes pour détecter des défauts de jets d'encre
EP1381864A4 (fr) Detection du candida
WO2005050203A3 (fr) Materiaux biologiques et utilisations correspondantes
WO2008109075A3 (fr) Biomarqueurs et procédés pour déterminer une sensibilité à des antagonistes de ctla-4
WO2003046531A3 (fr) Procede de detection de defauts
WO2005081783A3 (fr) Procedes pour determiner et quantifier l'exposition a des rayonnements ou a des genotoxines
WO2005031005A3 (fr) Compositions, methodes et kits de detection de la presence de trichomonas vaginalis dans un echantillon d'essai
WO2004057341A3 (fr) Dosage permettant d'indiquer un risque de maladie cardiovasculaire
WO2004057336A3 (fr) Utilisation de la nicotinamide n-methyltransferase comme marqueur du cancer colorectal
WO2005119209A3 (fr) Systeme et procede d'analyse de croissance microbienne
WO2003102015A3 (fr) Procede et appareil de detection et de suivi de peptides, et peptides identifies par ces moyens
WO2008063663A3 (fr) Dosages à base de poly(éthylèneglycol) pour la détection d'anticorps et trousses destinées à la mise en oeuvre de ces dosages
WO2003076896A3 (fr) Utilisation de biomarqueurs pour detecter le cancer du sein
EP1170591A3 (fr) Méthodes pour l'identification des combinaisons d'entités comme thérapeutiques
NO20053276L (no) Fremgangsmate og hjelpemiddel for pavisning av mykoplasma.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2546401

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 547296

Country of ref document: NZ

Ref document number: 2006540577

Country of ref document: JP

Ref document number: 2827/DELNP/2006

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2004292013

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004798515

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2004292013

Country of ref document: AU

Date of ref document: 20041115

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004292013

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200480040637.8

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2004798515

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2004798515

Country of ref document: EP